～ Leveraging expertise in AI and life sciences to accelerate business development in the healthcare sector for portfolio companies ～

Bio Engineering Capital, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Yuki Shimabara; hereinafter “BEC”), which supports entrepreneurs in life science fields such as medical AI/DX and regenerative medicine, is pleased to announce the appointment of Ryota Mori as Director. This move aims to further enhance support for the business development, IPO strategy, and global expansion of our portfolio companies.

Background of the Appointment
Mr. Mori has led multiple research projects at institutions such as the University of Tokyo Graduate School, focusing on disease risk estimation based on individual genomic data. He also founded pluszero Inc., where he currently serves as CEO, and successfully led the company through its IPO. With deep expertise in both life sciences and AI technologies, including natural language processing, Mr. Mori’s appointment is expected to provide BEC’s portfolio companies with new growth opportunities by integrating cutting-edge AI development with specialized knowledge in the life sciences. His involvement will support the advancement of business strategies, IPO readiness, and global market expansion.

Comment from Ryota Mori, Director, Bio Engineering Capital

“The progress in life sciences is accelerating at an unprecedented pace, driven by advances in experimental technologies such as genome editing and analytical techniques powered by artificial intelligence. I truly believe that we are now entering a new era of bioengineering, and I feel extremely fortunate to be a part of this transformative period.

Having studied both biology and AI, and having been through the journey of founding a company and taking it public, I hope to contribute to the future of the companies we support and the industry as a whole. I also look forward to creating synergies between BEC and pluszero, and will do my utmost to support further advancements in the medical and healthcare fields.”

Profile: Ryota Mori
Ph.D. in Science, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo.As a JSPS Research Fellow (DC1), conducted research specializing in epigenomic and RNA sequencing analysis, and developed AI-based algorithms and software using mathematical methods.In July 2018, founded pluszero Inc., an AI R&D company, and currently serves as its CEO. The company specializes in custom AI development tailored to client needs, conducts fundamental research in natural language processing, and offers related services.In October 2022, led pluszero to a successful listing on the Tokyo Stock Exchange Growth Market.Also serves as a management advisor to an advanced robotics R&D firm.

Comment from Yuki Shimabara, CEO, Bio Engineering Capital
“The convergence of life sciences and AI is a crucial frontier driving the evolution of the medical and healthcare industries. Mr. Mori brings a unique combination of scientific expertise, AI-driven solution development, and hands-on entrepreneurial and IPO experience. His appointment will further accelerate the growth of our company and our portfolio startups, as we continue to create new value in this dynamic field.”